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Abstract We review the pharmacologic, interventional
and device programming treatment options for patients
with implantable cardioverter-deﬁbrillators who present
with acute heart failure and implantable cardioverter-deﬁ-
brillator shocks.
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Introduction
The management of implantable cardioverter-deﬁbrillator
(ICD) shocks and the programming of tachycardia therapies
during acute heart failure syndromes is a topic of signiﬁcant
clinical importance, yet with limited data to guide evidence-
based recommendations. Implantation of ICDs has been
standard of care for resuscitated cardiac arrest and unstable
ventricular arrhythmias since the 1990s, based on studies
such as the Antiarrhythmics versus Implantable Deﬁbrilla-
tors (AVID) trial [1, 2, 3]. Implantation of ICDs for primary
prevention of sudden cardiac death in patients with left
ventricular dysfunction became widely accepted after the
MADIT II and SCD-HeFT studies were published in 2002
and 2005, respectively [4, 5].
Previous studies have shown that patients who receive
appropriate ICD therapy are at higher risk for heart failure
hospitalizations and mortality [6]. However, for ICD
shocks occurring in the setting of acute heart failure,
decisions regarding ICD programming as well as medical
and interventional therapy are often based on small studies,
expert opinion or personal experience within the cardiac
electrophysiology community.
Medical therapy
Arrhythmias and ICD therapies in cardiomyopathy patients
are often related to heart failure exacerbation and associated
volume overload. ICDs with heart failure monitoring capa-
bilities, such as intrathoracic impedance monitoring (Opti-
vol, Medtronic, Minneapolis, MN), often show correlation
between arrhythmias and volume overload episodes (Fig. 1).
Aggressivetreatmentofvolumeoverloadandoptimizationof
heart failure treatments, includingbetablockers,angiotensin-
converting enzyme (ACE) inhibitors, and aldosterone antag-
onistsiscritical.Afterloadreductionanddiuresiscandecrease
left ventricular (LV) wall stress and positively impact the
arrhythmic substrate, and may also increase cardiac output
sufﬁcientlytoavoidtheneedforinotropicsupport.Theseand
other beneﬁcial effects probably contribute to the decreased
frequency of supraventricular and ventricular arrhythmias
seen in one study of ACE inhibitor therapy [7].
After correcting volume overload, titrating up to the
maximum tolerated beta blocker dose is an essential
medical intervention. Besides reducing hospitalizations and
mortality, higher doses of beta blockers appear from the
MADIT-II trial to decrease the frequency of ventricular
tachycardia (VT) and ventricular ﬁbrillation (VF) requiring
ICD shocks [8].
There is some concern that high-dose beta blockers may
lead to more ventricular pacing, resulting in dyssynchrony
and possibly a further decrease in ventricular function.
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123However, in the acute setting, the focus should be on the
management of ventricular arrhythmias and patient symp-
toms, including shocks. In the longer term, if optimal beta
blocker dose results in obligate univentricular pacing,
consideration can be given to upgrading to a cardiac
resynchronization (CRT) device for improved ventricular
synchrony.
Although ICD therapy is life-saving, patients presenting
with recurrent ICD therapy and no reversible cause fre-
quently require antiarrhythmic drugs to decrease the
frequency of shocks. The primary indication for antiar-
rhythmic drug therapy in ICD patients is VT. However,
inappropriate shocks due to rapid supraventricular
arrhythmias, can account for up to 27% of all shocks
delivered to ICD patients based on data from SCD-HeFT
[9]. Such inappropriate shocks were also associated with
increased mortality in this population. Aggressive treat-
ment of supraventricular arrhythmias is important as well.
In the presence of underlying cardiomyopathy, both
ischemic and non-ischemic, the choice of antiarrhythmic
medications is limited. Data from the CAST trial [10]
demonstrated increased mortality associated with the use of
class IC agents such as ﬂecainide in the treatment of ven-
tricular ectopy in patients with prior myocardial infarction.
Sotalol is a class III agent not recommended in the setting
of severe cardiomyopathy based on data from studies such
as the SWORD trial [11]. However, it is still frequently
used as a second line agent if an ICD is already present. A
study by Paciﬁco and colleagues demonstrated a signiﬁcant
reduction in frequency of shocks in patients treated with
sotalol [12]. Furthermore, sotalol may decrease the deﬁ-
brillation threshold [13], and therefore may be a reasonable
choice in patients requiring antiarrhythmic therapy who
also demonstrate elevated deﬁbrillation threshold.
Studies on amiodarone and dofetilide, both class III
agents, show no evidence of increased mortality in heart
failure patients. A recent meta-analysis demonstrated a
statistically signiﬁcant decrease in sudden cardiac death
(SCD) and cardiovascular death in patients treated with
amiodarone [14]. However, there is no evidence suggesting
decreased all-cause mortality with amiodarone therapy
from large controlled trials [5]. Amiodarone added to a
beta blocker has been shown to signiﬁcantly decrease ICD
shocks compared to beta blocker alone or sotalol [15].
There is appropriate concern regarding amiodarone use in
younger patients due to the risk of long-term side effects.
Dofetilide may be an alternative based on the DIA-
MOND-CHF study [16]. In this study, the dofetilide group
had fewer hospitalizations as well as improved rhythm
control in the subset of patients with atrial ﬁbrillation.
Torsades de pointes did occur in 3.3% of patients in the
dofetilide group versus none in the placebo group, so this
drug may not be appropriate in patients without a
previously placed ICD. Due to its renal clearance, use of
this medication is often limited by renal insufﬁciency, and
the requirement for in-hospital initiation of the drug is
another signiﬁcant limitation.
Dronedarone is a new antiarrhythmic drug chemically
similar to amiodarone, but lacking the iodine moiety
appears to have less thyroid and pulmonary toxicity. It is
contraindicated in the setting of severe heart failure based
on the results of the ANDROMEDA study, which dem-
onstrated an increased mortality due to worsening heart
failure in the treatment group [17]. However, it was shown
to decrease hospital admissions and overall mortality in
patients with atrial ﬁbrillation, and mild to moderate heart
failure in the ATHENA trial [18].
Interventional therapy
In the ischemic cardiomyopathy population, ischemia may
exacerbate acute heart failure and associated arrhythmias.
Prompt assessment and treatment of unstable or ﬂow-
limiting coronary stenosis should be undertaken. Acute
ischemia is an uncommon cause of monomorphic VT,
which is more commonly related to reentry associated with
ventricular scar from chronic myocardial infarction or
ﬁbrosis from underlying non-ischemic cardiomyopathy.
Acute ischemia more commonly causes polymorphic VT
or ventricular ﬁbrillation. However, if the ischemia causes
worsening heart failure and volume overload, it can lead to
increased frequency of all types of ventricular arrhythmias
and therefore should be treated aggressively.
Other non-device-related interventions can also be
helpful in the setting of recurrent ICD shocks during an
acute heart failure exacerbation. Intra-aortic balloon
counterpulsation may help reduce afterload, improve cor-
onary perfusion, and relieve acute ischemia, aiding the
stabilization of recurrent arrhythmias.
Patients admitted with an acute heart failure exacerba-
tion and recurrent ICD shocks resistant to medical and
invasive interventions may require intubation and sedation,
both for patient comfort and to decrease the sympathetic
surge associated with ventricular arrhythmias. The poten-
tial role of the sympathetic nervous system in the initiation
and maintenance of ventricular arrhythmias must be con-
sidered [19, 20]. Schwartz and colleagues [21, 22, 23]
demonstrated that left cardiac sympathetic denervation
increases ventricular refractoriness and raises ventricular
ﬁbrillation threshold. Deep sedation may beneﬁcially
decrease the elevated adrenergic tone seen in this patient
population. Other potential treatment options that reduce
cardiac sympathetic stimulation are still being assessed,
including thoracic epidural anesthesia and left cardiac
sympathetic denervation [24, 25]. These interventions are
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123potential future treatment options with promising early
results.
Device programming
Initial ICD management and programming in the setting of
acute heart failure should involve assessment of the system
to ensure appropriate device and lead function, and to rule
out lead fracture, insulation defects, or dislodgement.
Stored events should be assessed to determine if appro-
priate therapies were delivered for ventricular arrhythmias,
or if inappropriate shocks resulted from supraventricular
tachycardia (SVT), T wave or QRS double counting,
electromagnetic or myopotential oversensing, or noise such
as from a loose set screw or lead fracture. Once appropriate
device function has been conﬁrmed, the arrhythmia events
can be analyzed to guide further decisions on programming
and treatment options.
Patients implanted with an ICD for primary prophylaxis
of sudden cardiac death are often programmed with
empiric VT and VF zones based on age and physician
preference. Patients with signiﬁcant ventricular scar,
especially those taking antiarrhythmic drugs, can develop
relatively slow VT which may fall outside the selected VT
detection and treatment zones.
When such a scenario is identiﬁed, a reasonable ﬁrst
response is to reprogram the VT zone to a longer cycle
length to ensure therapy for the clinical tachycardia. If the
tachycardia is hemodynamically tolerated, attempts should
be made to treat with anti-tachycardia pacing (ATP) as
initial therapy to avoid shocks. Further, the number of
ventricular beats in a given zone needed to deﬁne a
detection of VT episode should be high enough to avoid
treating non-sustained events.
It is still debated whether ICD shocks are simply a
marker of worsening underlying cardiomyopathy, or whe-
ther the shock itself directly contributes to worsened out-
comes. There are data showing myocardial damage from
ICD shocks [26, 27]. Further, a recent analysis by Sweeney
and colleagues[28] reviewing device therapy trials found
that patients receiving shocks compared to ATP had
increased mortality after controlling for other known risk
factors, suggesting that the shock itself contributed to
increased mortality. In combination with previous evidence
from MADIT-II and SCD-HeFT showing increased mor-
tality after appropriate shocks [6, 9, 29], this suggests that
aggressive programming of ATP in the fast VT zone as in
the PAINFREE [30] and PAINFREE II trials [31] is safe
and reasonable. In a recent study [32], Bhavnani and col-
leagues used multivariate analysis to compare shocks for
device testing with shocks for clinical arrhythmias.
Although there was no increased mortality associated with
shocks done to test device sensing and deﬁbrillation
threshold (DFT), mortality was higher in patients with
appropriate shocks, suggesting that the underlying sub-
strate plays a signiﬁcant role in outcomes and not simply
the shock itself.
While there is evidence that ICD shocks can be dele-
terious to cardiac function, one can also make the argument
that clinical VT unresponsive to previous ATP therapy may
be better treated with immediate shock. If ATP is not
successful, the cumulative time spent in VT will increase,
and this may also predict worse outcomes [28]. Therefore,
for patients that do not respond to ATP for a given sus-
tained tachyarrhythmia, an immediate shock may be the
best treatment option.
Results of the DAVID trial [33] demonstrated that high
rates of univentricular pacing increased the combined
endpoint of death or hospitalization for heart failure. Given
this data, devices should be programmed to minimize
unnecessary ventricular pacing. Programming changes,
including decreasing base pacing rate and increasing
atrioventricular (AV) interval in patients with dual cham-
ber devices should be considered. This is of particular
importance if device interrogation demonstrates that an
increase in ventricular pacing correlates with the heart
failure episode. This must of course be considered along
with the patient’s tolerance of slower ventricular rates. If
increased need for ventricular pacing is due to progression
of underlying conduction system disease or is a response to
necessary high-dose beta blockade, the addition of a cor-
onary sinus lead for more optimal intraventricular syn-
chrony with biventricular pacing should be considered.
Patients frequently undergo deﬁbrillation threshold
testing (DFT) at or near the time of ICD implantation to
assess detection and therapy for ventricular ﬁbrillation
(VF). While DFT testing remains standard for both primary
and secondary prevention device implants, many cardiac
electrophysiologists are now omitting DFT testing for
primary prevention patients. This is based on large part of
published trials demonstrating high deﬁbrillation success
rates with newer devices (97.8% in the SCD-HeFT trial)
and a small but concerning risk associated with DFT test-
ing itself. In addition, the correlation between deﬁbrillation
threshold at implantation (prolonged anesthesia, supine
position, induced VF), and real-world clinical VT or VF is
unclear. In long-term follow-up, initial shocks for clinical
ventricular arrhythmias had a success rate of 80–100%
regardless of implant DFT [34]. While infrequent, patients
with adequate safety margin DFT at implant testing (usu-
ally 10 joules), may develop recurrent ventricular
arrhythmias refractory to ICD therapies in the setting of
acute heart failure. Management of these cases necessitates
aggressive medical management of the acute heart failure
and volume overload with consideration for repeat DFT
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123testing and possible ICD system revision, prior to discharge
to ensure successful therapy in the future.
Unsuccessful deﬁbrillation after a clinical ventricular
arrhythmia may require changes to the deﬁbrillator system.
Non-invasive options include repeat DFT testing utilizing
alternative shocking vectors, which in an individual patient
may provide a lower DFT. Invasive options include addi-
tion of a new RV pace/sense lead if sensing of VF is the
issue, or addition of a new RV shocking lead if the current
lead is dysfunctional or in a suboptimal position. Addition
of a subcutaneous array, SVC coil, or azygous vein lead
[35] may also be considered to alter the shocking vector
and include more of the left ventricle (LV) in the shocking
ﬁeld.
Evaluation of device proarrhythmia
Biventricular ICDs and pacemakers have been demon-
strated to improve NYHA functional class, decrease heart
failure hospitalizations, and decrease mortality in properly
selected patients [36, 37]. However, case reports and case
series have demonstrated the potential proarrhythmic
effects of biventricular devices [38, 39]. These events are
relatively rare, and proposed mechanisms include increased
dispersion of refractoriness, prolonged QT interval, and
atypical autonomic response. The LV lead may induce
premature ventricular beat triggers or activate scar-related
regions of slow conduction to facilitate reentry. Such
atypical responses are infrequent and there are no clear
predictors of such a response. However, if a patient pre-
sents with heart failure and ventricular arrhythmias after a
recent biventricular device implantation, it is reasonable to
consider temporarily discontinuing LV pacing to determine
if this will decrease arrhythmic events, which has been
demonstrated in some case series [40].
Catheter ablation
Catheter ablation of VT is moving from a palliative pro-
cedure to being used as an earlier preemptive treatment
strategy. Recent studies showing improved clinical efﬁcacy
(up to 75% success at 1 year) and acceptable complication
rates given the high-risk substrate, include the Multicenter
Thermocool Ventricular Ablation trial [41] and the Sub-
strate Mapping and Ablation in Sinus Rhythm to Halt
Ventricular Tachycardia trial (SMASH VT) [42]. This
evolving role for VT ablation is reﬂected in the recently
published EHRA/HRS Expert Consensus on Catheter
Ablation of Ventricular Arrhythmias [43]. While acute
heart failure admission was not an exclusion criterion for
THERMOCOOL and SMASH-VT, no ablation studies to
date have sought to enroll patients speciﬁcally in the setting
of acute heart failure [44].
It should be recognized that prolonged ablation proce-
dures in the setting of acute heart failure may substantially
increase peri-procedural risks due to prolonged supine
Fig. 2 Combined endocardial and epicardial mapping (left)o f
nonischemic substrate presenting with VT storm. Red dots on
epicardial map (right) created with CARTO electroanatomical
mapping system (Biosense Webster, Diamond Bar, CA) represent
ablation lesions at the site of origin of VT
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123position, protracted anesthesia, and potential volume
loading associated with externally irrigated ablation cath-
eters. Therefore, optimization of volume status is essential
prior to consideration for VT ablation. In patients with
electrical storm which persists despite aggressive man-
agement of acute heart failure and antiarrhythmic drug
therapy, substrate-based ablation of unstable VT in sinus
rhythm guided by electroanatomic mapping systems has
been demonstrated to be effective for preventing arrhyth-
mic recurrence [44, 45] (Fig. 2).
Ablation should also be considered when recurrent
supraventricular arrhythmias other than atrial ﬁbrillation
cause inappropriate ICD therapies. Reentrant arrhythmias
such as AV nodal reentrant tachycardia or atrial ﬂutter can
occasionally be interpreted as VT or VF by the ICD and
lead to inappropriate shocks (Fig. 3). Such rhythms can be
difﬁcult to manage medically and have a high cure rate
with catheter ablation.
Atrial ﬁbrillation (AF) frequently coexists with ven-
tricular arrhythmias in the cardiomyopathy population.
Atrial ﬁbrillation with rapid ventricular rates can lead to
ICD shocks despite algorithms meant to differentiate it
from VT. Use of a dual chamber device and various atrial
ﬁbrillation discrimination algorithms can help but are not
fail-safe. When medical therapy fails, consideration can be
given to atrial ﬁbrillation ablation. If the AF is refractory to
ablation or the patient is not a candidate, and the rate
cannot be adequately controlled, then AV nodal ablation
with biventricular pacing is an alternative [46].
Conclusion
Responding to ICD shocks and programming ICD thera-
pies in the setting of acute heart failure involves a com-
bination of medical, interventional, and device-based
interventions. Cardiac electrophysiologists and heart fail-
ure specialists must work in collaboration to optimize the
underlying substrate, treat precipitating factors and pro-
gram the patient’s device to ensure successful therapy
while minimizing the number of ICD shocks.
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